论文部分内容阅读
使用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测恶性黑素瘤患者外周血中酪氨酸酶ｍＲＮＡ，并与健康供血者和其它皮肤恶性肿瘤患者对照。结果：６８例恶性黑素瘤患者，临床Ⅰ期和Ⅱ期酪氨酸酶ｍＲＮＡ的ＲＴ－ＰＣＲ阳性率分别为６．５％和１３．３％，Ⅲ期为４２．９％，Ⅳ期（即有远距离转移者）为８７．５％（Ｐ＜０．００１）。说明外周血中酪氨酸酶ｍＲＮＡ阳性率与临床分期有明显的关系，而与性别、肿瘤发病部位和病理学分类无关（Ｐ＞０．０５）。在健康供血者和其他皮肤恶性肿瘤患者血液中酪氨酸酶ｍＲＮＡ的ＲＴ－ＰＣＲ均为阴性。提示酪氨酸酶ｍＲＮＡ具有特异性。
Tyrosinase mRNA in peripheral blood of patients with malignant melanoma was detected by reverse transcription polymerase chain reaction (RT-PCR) and compared with healthy donors and other skin cancer patients. RESULTS: In 68 malignant melanoma patients, the positive rate of RT-PCR for clinical stage I and II tyrosinase mRNA were 6.5% and 13.3%, respectively, and 42.9% for stage III. That is, distant metastasis was 87.5% (P<0.001). The positive rate of tyrosinase mRNA in peripheral blood was significantly correlated with clinical stage, but not with gender, tumor location, and pathological classification (P>0.05). Tyrosinase mRNA was negative in RT-PCR in the blood of healthy blood donors and other skin malignancies. Tyrosinase mRNA is suggested to have specificity.